This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and ...
Takeda ( TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of ...
Abstract: Leakage power is currently the most important factor in determining whether a circuit is a suitable for lowpower VLSI circuit or not. There are numerous methods to decrease power dissipation ...
The MarketWatch News Department was not involved in the creation of this content. -- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is ...
Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The ...
STOCKHOLM, Jan. 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results